Loading…
Chinese maker of surgical robotic systems for minimally invasive laparoscopic and endoscopic surgery.
Chinese maker of surgical robotic systems for minimally invasive laparoscopic and endoscopic surgery.
In one line: China's answer to a smaller Intuitive Surgical.
Moat: narrow (IP / patents, regulatory licence, switching costs). Regulatory approvals and surgeon training/installed base create switching costs once a hospital adopts a robotic platform.
Headquarters: Shenzhen, China · Employees: 602
Size Shenzhen Edge Medical (2675.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $1.31B, the 528th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$26.34 on 6 Nov 2026.
Performance Over six months the shares fell 50.6%, against -3.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 132.2% over the last twelve months (peer median +14.5%); the operating margin is 2.0% (peer median 16.0%).
Valuation It trades at 130.1× forward earnings against a peer median of 25.2× (most expensive of 16).
Capital Return on invested capital runs 5.9 points below its cost of capital (7.9% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | HK$699M | HK$494M | HK$173M | HK$53.1M | HK$0 |
| Revenue growth | — | +185% | +227% | — | — |
| Gross profit | HK$457M | HK$318M | HK$93.7M | HK$18.2M | -HK$8.00M |
| EBITDA | HK$37.0M | -HK$61.3M | -HK$282M | -HK$277M | -HK$327M |
| Net income | -HK$21.4M | -HK$96.1M | -HK$237M | -HK$235M | -HK$290M |
| Free cash flow | -HK$244M | -HK$213M | -HK$270M | -HK$420M | -HK$142M |
| Capital expenditure | HK$16.6M | HK$3.88M | HK$29.3M | HK$70.3M | HK$9.01M |
| Total debt | n/a | HK$11.0M | HK$19.2M | HK$29.4M | HK$18.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Edge Medical 2675.HK | $1.31B | -51% | +132% | 2% | 130.1× | n/a |
| Intuitive Surgical ISRG | $157B | +1% | +20% | 32% | 37.5× | 30.8% |
| Shanghai MicroPort MedBot (Group) 2252.HK | n/a | -26% | n/a | n/a | n/a | n/a |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2675.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.5% | +5.7% | 4th lowest of 21 |
| 6-month return | -50.6% | -3.3% | 2nd lowest of 21 |
| Distance from 52-week high | -64.3% | -34.3% | 3rd lowest of 21 |
| Revenue growth (TTM) | +132.2% | +14.5% | highest of 20 |
| Operating margin | 2.0% | 16.0% | 7th lowest of 20 |
| Forward P/E | 130.1× | 25.2× | most expensive of 16 |
| ROIC minus cost of capital | -5.9 pp | +0.9 pp | 6th lowest of 20 |
| Net debt / EBITDA | -56.7× | -0.5× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |